
CLAIMS

1. A compound of the formula [I-c], or a pharmaceutically acceptable salt thereof:




[I-c]

wherein

R^1 is

(1) the formula:



wherein

R^{1a} is C_{1-4} alkyl,

R^{1b} is C_{1-4} alkyl or trifluoromethyl, and

R^{1c} is


(a) C_{1-4} alkyl,

(b) C_{1-4} fluoroalkyl,

(c) C_{1-4} alkoxy, or

(d) C_{1-4} alkoxy C_{1-4} alkyl, or

(2) the formula:



wherein

n is 1, 2, 3, 4 or 5, and

R^{1d} is

(a) fluoro,

(b) C_{1-4} alkyl,

(c) C_{1-4} fluoroalkyl,


(d) C_{1-4} alkoxy, or

(e) C_{1-4} alkoxy C_{1-4} alkyl,

R^2 is hydrogen, and

R^6 is 1-methylbutyl or n-hexyl.

2. The compound or pharmaceutically acceptable salt according to claim 1, wherein R^1 is the formula:



wherein

R^{1a} is C_{1-4} alkyl,


R^{1b} is C_{1-4} alkyl or trifluoromethyl, and

R^{1c} is

(b) difluoromethyl or trifluoromethyl, or

(c) methoxy.

3. The compound or pharmaceutically acceptable salt according to claim 1, wherein R^1 is the formula:



wherein

n is 3, 4 or 5, and

R^{1d} is

(a) fluoro,

(c) C_{1-4} fluoroalkyl,

(d) methoxy, or


(e) methoxymethyl.

4. The compound or pharmaceutically acceptable salt according to claim 3, wherein


n is 3 or 4, and

R^{1d} is monofluoromethyl, difluoromethyl or trifluoromethyl.

5. A compound selected from the following formulas:









or a pharmaceutically acceptable salt thereof.

6. A compound of the following formula:




or a pharmaceutically acceptable salt thereof.

7. A compound of the following formula:



or a pharmaceutically acceptable salt thereof.

8. A compound of the following formula:



or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8, and a pharmaceutically acceptable carrier.

10. An mPGES-1 inhibitor comprising the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8.

11. A therapeutic or prophylactic agent for pain, rheumatism, fever, osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple sclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer, which comprises the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8.

12. A therapeutic or prophylactic agent for glaucoma and/or ocular hypertension, which comprises the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8, and one or more kinds of other therapeutic agents for glaucoma in combination.

13. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 for the production of an mPGES-1 inhibitor.

14. Use of the compound or pharmaceutically acceptable salt

according to any one of claims 1 to 8 for the production of a therapeutic or prophylactic agent for pain, rheumatism, fever, osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple sclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer.

15. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 for the production of a therapeutic or prophylactic agent for glaucoma and/or ocular hypertension, in combination with one or more kinds of other therapeutic agents for glaucoma.

16. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 for use as a medicament.

17. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 for use in the treatment or prophylaxis of pain, rheumatism, fever, osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple sclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer.

18. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 for use in the treatment or prophylaxis of glaucoma and/or ocular hypertension, and for use in combination with one or more kinds of other therapeutic agents in the treatment of glaucoma.

19. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment or prophylaxis of pain, rheumatism, fever, osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple sclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer.

20. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment or prophylaxis of glaucoma and/or ocular hypertension, in combination with one or more kinds of other therapeutic agents for the treatment of glaucoma.